You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)中期淨利預增超135%
格隆匯 07-14 07:34

格隆匯7月14日丨藥明生物(02269.HK)發佈公吿,集團預期截至2021年6月30日止六個月所錄得的歸屬於公司權益股東的利潤相比於去年同期歸屬於公司權益股東的利潤增長135%以上。

公吿表示,該增長主要是由於:(i)集團於2021年上半年加速高效推進執行現存及新引進的COVID-19項目,支持並賦能全球客户抗疫並相應提升收益;(ii)憑藉領先的技術平台、行業最佳的項目交付時間及優秀的項目執行過往記錄,集團的新綜合項目收益和市場份額顯著增加;(iii)成功執行“贏得藥物分子”戰略,從而在研發管線中引入更多後期項目並提高近期收益;(iv)2020年第一季度受疫情影響而短暫降低的生產效率已經完全恢復;(v)現有產能和資源利用率的持續提升、以及運營效率改善項目的執行極大提高毛利率和運營利潤率;以及(vi)集團持有的上市及未上市投資組合的公允價值變動推高投資收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account